• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Disease-modifying antirheumatic drugs (DMARDs)

DMARDs are drugs capable of modifying the progression of rheumatic disease. The term is, however, applied to what are now considered to be traditional disease-modifying drugs, in particular sulfasalazine, methotrexate and ciclosporin, as well as azathioprine, cyclophosphamide, antimalarial drugs, penicillamine and gold. The newer agent, leflunomide, may be included as a DMARD. The biologics, such as etanercept and infliximab, are not generally referred to as DMARDs.